KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2025)

Historic Long-Term Deferred Tax for Vertex Pharmaceuticals (VRTX) over the last 9 years, with Q3 2025 value amounting to $2.9 billion.

  • Vertex Pharmaceuticals' Long-Term Deferred Tax rose 2721.21% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 2721.21%. This contributed to the annual value of $2.3 billion for FY2024, which is 2864.08% up from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Long-Term Deferred Tax is $2.9 billion, which was up 2721.21% from $2.7 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $2.9 billion during Q3 2025, with a 5-year trough of $815.9 million in Q1 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Long-Term Deferred Tax had a median value of $1.5 billion in 2023 and averaged $1.7 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Long-Term Deferred Tax crashed by 2891.12% in 2021 and then surged by 4871.42% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $934.5 million in 2021, then skyrocketed by 33.43% to $1.2 billion in 2022, then skyrocketed by 45.33% to $1.8 billion in 2023, then rose by 28.64% to $2.3 billion in 2024, then rose by 26.0% to $2.9 billion in 2025.
  • Its last three reported values are $2.9 billion in Q3 2025, $2.7 billion for Q2 2025, and $2.5 billion during Q1 2025.